Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Chemed Corp (CHE)

NYSE: CHE · Services-Home Health Care Services · Cincinnati, OH

Our rating: Neutral

Neutral reaffirmed at $534.72, moderate conviction, October 30, 2026.

Breaks if: The Neutral call turns Cautious if net margin falls below 9% for two consecutive quarters — a clear sign that reimbursement pressure or cost inflation is eroding franchise economics the current multiple does not discount. It turns Positive if revenue growth accelerates above 7% and holds there for two consecutive quarters while the FCF yield stays at or above 4%, indicating the growth trajectory has genuinely shifted rather than bouncing from a soft patch.

Key figures

Market value$7.1B
Revenue, last 12 months$2.7B
Net income, last 12 months$282M
Free cash flow, last 12 months$295M
Price to earnings25.3×
Free cash flow yield4.1%
Dividend yield0.5%
Operating margin13.9%
Return on equity29.1%
Beta to the S&P 5000.23
Volatility, annualized28.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$691M10.6%$5.45$38M
June 30, 2026$673M8.8%$5.13$69M
March 31, 2026$658M1.6%$4.84$71M
December 31, 2025$639M55.6%$5.45$117M
September 30, 2025$625M59.7%$4.46$66M
June 30, 2025$619M65.2%$3.57$123M
March 31, 2025$647M82.7%$4.86$19M
December 31, 2024$411M17.4%$6.01$152M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

10 ledger entries and 15 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.